BACKGROUND: Primary cutaneous head and neck melanomas (HNM) are reported to be associated with a higher incidence of brain metastasis than trunk and limb melanomas (TLM). In this study, the incidence of brain metastases in patients with HNM and risk factors for the development of brain metastases were analyzed. METHODS: From a large, prospectively-collected database, 1,687 HNM patients and 8,793 TLM patients who presented with American Joint Committee on Cancer (AJCC) stage I and II disease were identified. Survival was assessed using the Kaplan-Meier method and multivariate Cox regression analysis. Independent risk factors were determined by binary logistic regression analysis. RESULTS: The incidence of brain metastases 5 years after diagnosis of HNM was 6.7 % compared with 4.7 % for brain metastases from TLM (p = 0.003). Patients with scalp melanomas were most likely to develop brain metastases (12.7 %). Independent risk factors for brain metastasis in patients with HNM were Breslow thickness, ulceration, and scalp location. CONCLUSION: Patients with primary scalp melanomas had a much higher incidence of brain metastasis than patients with melanomas on other head and neck sites, who in turn had a higher incidence than patients with melanomas on sites elsewhere on the body. More intensive monitoring of patients with scalp melanomas, who are at particularly high risk of brain metastasis, might lead to earlier discovery of metastatic disease in the brain, offering the prospect of earlier intervention and better outcomes.
BACKGROUND: Primary cutaneous head and neck melanomas (HNM) are reported to be associated with a higher incidence of brain metastasis than trunk and limb melanomas (TLM). In this study, the incidence of brain metastases in patients with HNM and risk factors for the development of brain metastases were analyzed. METHODS: From a large, prospectively-collected database, 1,687 HNM patients and 8,793 TLM patients who presented with American Joint Committee on Cancer (AJCC) stage I and II disease were identified. Survival was assessed using the Kaplan-Meier method and multivariate Cox regression analysis. Independent risk factors were determined by binary logistic regression analysis. RESULTS: The incidence of brain metastases 5 years after diagnosis of HNM was 6.7 % compared with 4.7 % for brain metastases from TLM (p = 0.003). Patients with scalp melanomas were most likely to develop brain metastases (12.7 %). Independent risk factors for brain metastasis in patients with HNM were Breslow thickness, ulceration, and scalp location. CONCLUSION:Patients with primary scalp melanomas had a much higher incidence of brain metastasis than patients with melanomas on other head and neck sites, who in turn had a higher incidence than patients with melanomas on sites elsewhere on the body. More intensive monitoring of patients with scalp melanomas, who are at particularly high risk of brain metastasis, might lead to earlier discovery of metastatic disease in the brain, offering the prospect of earlier intervention and better outcomes.
Authors: Lauren E Haydu; Serigne N Lo; Jennifer L McQuade; Rodabe N Amaria; Jennifer Wargo; Merrick I Ross; Janice N Cormier; Anthony Lucci; Jeffrey E Lee; Sherise D Ferguson; Robyn P M Saw; Andrew J Spillane; Kerwin F Shannon; Jonathan R Stretch; Patrick Hwu; Sapna P Patel; Adi Diab; Michael K K Wong; Isabella C Glitza Oliva; Hussein Tawbi; Matteo S Carlino; Alexander M Menzies; Georgina V Long; Alexander J Lazar; Michael T Tetzlaff; Richard A Scolyer; Jeffrey E Gershenwald; John F Thompson; Michael A Davies Journal: J Clin Oncol Date: 2020-01-28 Impact factor: 44.544
Authors: Kelly E Flanagan; Laura J Burns; James T Pathoulas; Chloe J Walker; Isabel Pupo Wiss; Kristine M Cornejo; Maryanne M Senna Journal: Skin Appendage Disord Date: 2021-06-16
Authors: Marloes Faut; Kevin P Wevers; Robert J van Ginkel; Gilles F H Diercks; Harald J Hoekstra; Schelto Kruijff; Lukas B Been; Barbara L van Leeuwen Journal: Ann Surg Oncol Date: 2016-09-19 Impact factor: 5.344
Authors: Tyler Cardinal; Dhiraj Pangal; Ben A Strickland; Paul Newton; Saeedeh Mahmoodifar; Jeremy Mason; David Craig; Thomas Simon; Ben Yi Tew; Min Yu; Wensha Yang; Eric Chang; Ryan P Cabeen; Jacob Ruzevick; Arthur W Toga; Josh Neman; Bodour Salhia; Gabriel Zada Journal: Neurooncol Adv Date: 2021-11-18
Authors: Renee P Wood; Jane S Heyworth; Nina S McCarthy; Audrey Mauguen; Marianne Berwick; Nancy E Thomas; Michael J Millward; Hoda Anton-Culver; Anne E Cust; Terence Dwyer; Richard P Gallagher; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Eric K Moses; Colin B Begg; Sarah V Ward Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-20 Impact factor: 4.254
Authors: Mani Ratnesh S Sandhu; Veronica L Chiang; Thuy Tran; James B Yu; Sarah A Weiss; Sarah B Goldberg; Mariam S Aboian; Harriet M Kluger; Amit Mahajan Journal: J Neurooncol Date: 2021-08-05 Impact factor: 4.130
Authors: Wolfram E Samlowski; James Moon; Merle Witter; Michael B Atkins; John M Kirkwood; Megan Othus; Antoni Ribas; Vernon K Sondak; Lawrence E Flaherty Journal: Cancer Med Date: 2017-10-10 Impact factor: 4.452